Innate Pharma Stock Forum

$Innate Pharma(IPHA.US)$
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Innate Pharma's Phase 1/2 trial of SAR443579 (SAR’579), developed with Sanofi, continues to show promising results for treating relapsed/refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). The clinical trial results, presented at the European Hematology Association 2024 Congress, hig...

$Innate Pharma(IPHA.US)$
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
Innate Pharma has announced positive results from its Phase 2 TELLOMAK study, evaluating lacutamab in patients with mycosis fungoides (MF), a type of cutaneous T cell lymphoma. The study, presented at ASCO 2024, included 107 heavily pretreated patients. Lacutamab demonstrated significant anti-tumor activity, with an objective response rate (ORR) of 22.4% per Olse...

$Innate Pharma(IPHA.US)$
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
Innate Pharma announced that five abstracts featuring its drug candidates have been accepted for presentation at the ASCO 2024 Annual Meeting, scheduled for May 31-June 4, 2024, in Chicago. Highlights include: - Topline results of the TELLOMAK Phase 2 trial for lacutamab in mycosis fungoides, confirming promising clinical activity. - Two posters on IPH6501, the second-generation ANKET® for CD20-...

$Innate Pharma(IPHA.US)$
NEWS
Innate Pharma: Clarification Regarding SAR443579 Designation
Innate Pharma, listed on Euronext Paris (IPH) and Nasdaq (IPHA), clarified that their molecule SAR443579/IPH6101 was incorrectly mentioned as having breakthrough designation in an abstract published for the European Hematology Association 2024 Congress. The correct status is that the molecule has received US FDA Fast Track Designation, as communicated in June 2023. This clarification aims to rectify the mi...

$Innate Pharma(IPHA.US)$
NEWS
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monothe...

$Innate Pharma(IPHA.US)$
NEWS
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
🔸Promising preclinical data for IPH4...

$Innate Pharma(IPHA.US)$
NEWS
Innate Pharma SA (Nasdaq: IPHA) executives to attend Van Lanschot Kempen conference in Amsterdam on April 16-17, 2024.

$Innate Pharma(IPHA.US)$ Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.10) per share. This is a 87.2 percent increase over losses of $(0.75) per share from the same period last year. The company reported $66.35 million in sales this quarter. This is a 12.71 percent increase over sales of $58.87 million the same period last year.

$Pfizer(PFE.US)$  Phase 2
$Leap Therapeutics(LPTX.US)$  Phase 2
$Vera Therapeutics(VERA.US)$  Phase 2b
$4D Molecular Therapeutics(FDMT.US)$  Phase 2
$Adverum Biotechnologies(ADVM.US)$  Phase 2
$Denali Therapeutics(DNLI.US)$  Phase 2
$Akero Therapeutics(AKRO.US)$  Phase 2b
$Spruce Biosciences(SPRB.US)$  Phase 2
$Xencor(XNCR.US)$  Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$  Phase 2
$Harmony Biosciences(HRMY.US)$  Phase 2
$Annexon(ANNX.US)$  Phase 2a
$Roivant Sciences(ROIV.US)$...

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...